Evgen Pharma
plc
("Evgen",
the "Company" or the "Group")
Change of
Name
and
Change of Company
Website
Alderley Park, UK - 25 April 2024: Evgen Pharma plc (AIM: EVG), the clinical stage drug
development company developing sulforaphane based medicines for the
treatment of multiple diseases, confirms that further to its
announcement on 19 March 2024, the Company's change of name to
TheraCryf plc and change of AIM ticker to TCF will become effective
tomorrow, 26 April 2024.
At the same time the Company
notifies shareholders that, pursuant to AIM Rule 26, its corporate
website will also change to www.theracryf.com
effective tomorrow.
- Ends
-
Enquiries
|
Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@evgen.com
|
|
Cavendish Capital Markets (NOMAD and
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet
Ward (ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
Evgen@Instinctif.com
|
About Evgen Pharma plc
Evgen Pharma is a clinical stage
drug development company developing sulforaphane based medicines
for the treatment of multiple diseases. The Company's core
technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane
and novel proprietary analogues based on sulforaphane.
The Company's lead clinical asset,
SFX-01, is a patented composition of synthetic sulforaphane and
alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a
Phase 1b study of the Company's new enteric coated tablet
formulation. The FDA has granted Orphan Drug status to SFX-01 in
malignant glioma. SFX-01 will be investigated initially in this
indication as an investigator sponsored study in the Netherlands
funded by a grant from the Netherlands government and Dutch Cancer
Society.
The Company also has a wide number
of collaborations with leading academic centres in the UK, Europe
and the US as part of the continuing strategy to build the
scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist
company in neurodevelopmental disorders, commencing with autism
spectrum disorder. The deal, if successful, will generate milestone
payments of $160.5m and a double-digit royalty on sales.
Evgen recently acquired
neuropsychiatry company Chronos Therapeutics Limited, now a wholly
owned affiliate of the Company The acquired assets comprise an
orexin-1 antagonist (Ox-1) in late pre-clinical development
targeting impulsivity and anxiety disorders and an atypical
dopamine transporter inhibitor (DAT) also in late pre-clinical
development for fatigue, e.g. due to long COVID or multiple
sclerosis and the orphan condition narcolepsy.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol EVG.
For further information, please
visit: www.evgen.com.